Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions

Yasuko Iwakiri1, Vijay Shah2, Don C Rockey3

  • 1The Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States.

Journal of Hepatology
|June 10, 2014
PubMed

Insights

Chronic liver disease alters liver vasculature, leading to portal hypertension. Understanding hepatic vascular cell signaling is key to developing new treatments for this condition.

Area of Science:

  • Vascular Biology
  • Hepatology
  • Gastroenterology

Background:

  • Chronic liver disease causes significant intra- and extrahepatic vascular changes.
  • Portal hypertension is closely linked to alterations in liver vasculature and vascular biology.
  • Hepatic vascular cells, including sinusoidal endothelial cells and hepatic stellate cells, play critical roles in liver fibrosis and portal hypertension pathogenesis.

Purpose of the Study:

  • To review the current understanding of the basic biology of portal hypertension.
  • To focus on the physiology, pathophysiology, and cell signaling within the liver and mesenteric vasculature.
  • To highlight translational implications and future research directions.

Main Methods:

  • This is a review article, synthesizing existing research.
  • Focuses on cellular and molecular mechanisms of portal hypertension.
  • Examines signaling pathways involving growth factors and vasoactive peptides.

Main Results:

  • Increased intra-hepatic resistance is an early feature of liver injury, driven by hepatic vascular cell changes.
  • Complex signaling pathways involving cytokines and vasoactive peptides contribute to portal hypertension.
  • Vascular changes in the liver propagate to the extrahepatic circulation, worsening portal hypertension through collateral formation and vasodilation.

Conclusions:

  • Hepatic vascular cells and their signaling pathways are central to the development of portal hypertension in chronic liver disease.
  • Understanding these mechanisms is crucial for developing targeted therapies.
  • Further research into cellular signaling and vascular dynamics holds promise for translational applications.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
41
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
44
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K